{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:44:32Z","timestamp":1769525072974,"version":"3.49.0"},"reference-count":89,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cancer patients have an incidence of about 60% kidney disease development and are at elevated risk of acute renal damage. Kidney disease in these patients is frequently associated with nephrotoxicity from the ongoing oncological treatment. New anticancer therapeutic strategies, such as targeted therapies and immunotherapies, offer substantial benefits in the treatment of many neoplasms. However, their use is associated with significant nephrotoxicity, which qualitatively differs from that seen with traditional cytotoxic chemotherapy, while the underlying mechanisms are complex and still to be clearly defined. Nephrologists need to be knowledgeable about the array of such renal toxicities for effective collaboration with the oncologist in the prevention and management of kidney involvement. Renal adverse effects may range from asymptomatic proteinuria to renal failure, and their prompt identification and timely treatment is essential for optimal and safe care of the patient. In this article, after presenting clinical cases we discuss the differing renal toxicity of three novel anticancer agents (aflibercept, dasatinib, and nivolumab) and possible measures to counter it.<\/jats:p>","DOI":"10.3390\/ijms21144878","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T09:25:28Z","timestamp":1594373128000},"page":"4878","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations"],"prefix":"10.3390","volume":"21","author":[{"given":"Luca","family":"Piscitani","sequence":"first","affiliation":[{"name":"Nephrology and Dialysis Unit, Department of Medicine, G. d\u2019Annunzio University, Chieti-Pescara, SS. Annunziata Hospital, Via dei Vestini, 66013 Chieti, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Sirolli","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, Department of Medicine, G. d\u2019Annunzio University, Chieti-Pescara, SS. Annunziata Hospital, Via dei Vestini, 66013 Chieti, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Di Liberato","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, Department of Medicine, G. d\u2019Annunzio University, Chieti-Pescara, SS. Annunziata Hospital, Via dei Vestini, 66013 Chieti, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manrico","family":"Morroni","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine-Neuroscience and Cell Biology, School of Medicine, Universit\u00e0 Politecnica delle Marche, Via Tronto 10\/A, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8466-6314","authenticated-orcid":false,"given":"Mario","family":"Bonomini","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, Department of Medicine, G. d\u2019Annunzio University, Chieti-Pescara, SS. Annunziata Hospital, Via dei Vestini, 66013 Chieti, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.kint.2019.04.043","article-title":"International conference on onco-nephrology participants. Summary of the international conference on onco-nephrology: An emerging field in medicine","volume":"96","author":"Capasso","year":"2019","journal-title":"Kidney Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5414\/CN109371","article-title":"Update on the nephrotoxicity of novel anticancer agents","volume":"89","author":"Nussbaum","year":"2018","journal-title":"Clin. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/17512433.2019.1613888","article-title":"The nephrotoxicity of new immunotherapies","volume":"12","author":"Sury","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11523-015-0368-7","article-title":"Renal toxicities of targeted therapy","volume":"10","author":"Abbas","year":"2015","journal-title":"Targ. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1681\/ASN.2018080853","article-title":"Therapeutic inhibition of VEGF signaling and associated nephrotoxicities","volume":"30","author":"Estrada","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: Therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"ref_7","first-page":"5391","article-title":"Up-regulation of vascular endothelial growth factor\/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels","volume":"56","author":"Larcher","year":"1996","journal-title":"Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/PAS.0b013e318243555b","article-title":"Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: An immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors","volume":"36","author":"Miettinen","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1074\/jbc.C300012200","article-title":"Neutralization of circulating vascular endothelial growth factor [VEGF] by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria","volume":"278","author":"Sugimoto","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.amjmed.2008.11.025","article-title":"Renal effects of anti-angiogenesis therapy: Update for the internist","volume":"122","author":"Gurevich","year":"2009","journal-title":"Am. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: A VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cncr.28972","article-title":"Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway","volume":"121","author":"Hamnvik","year":"2015","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signaling inhibition-induced proteinuria: Mechanisms significance and management","volume":"46","author":"Izzedine","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40261-014-0174-5","article-title":"Risk of hypertension in cancer patients treated with aflibercept: A systematic review and metaanalysis","volume":"34","author":"Qi","year":"2014","journal-title":"Clin. Drug Investig."},{"key":"ref_16","first-page":"H1054","article-title":"VEGF upregulates eNOS message, protein, and NO production in human endothelial cells","volume":"274","author":"Hood","year":"1998","journal-title":"Am. J. Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s11906-999-0016-7","article-title":"Role of nitric oxide in the control of renal function and salt sensitivity","volume":"1","author":"Zou","year":"1999","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.semnephrol.2010.09.007","article-title":"Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: Mechanisms and potential use as a biomarker","volume":"30","author":"Robinson","year":"2010","journal-title":"Semin. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"H1395","DOI":"10.1152\/ajpheart.01277.2005","article-title":"Mechanisms of endothelial response to oxidative aggression: Protective role of autologous VEGF and induction of VEGFR2 by H2O2","volume":"291","author":"Deudero","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/s41598-020-58994-5","article-title":"Predictive factors for the development of proteinuria in cancer patients treated with bevacizumab, ramucirumab, and aflibercept: A single-institution retrospective analysis","volume":"10","author":"Kanbayashi","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"H560","DOI":"10.1152\/ajpheart.00133.2005","article-title":"VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature","volume":"290","author":"Kamba","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MD.0000000000000207","article-title":"Kidney diseases associated with anti-vascular endothelial growth factor (VEGF) An 8-year observational study at a single center","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ki.2013.344","article-title":"Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy","volume":"85","author":"Izzedine","year":"2014","journal-title":"Kidney Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1093\/ndt\/gfl507","article-title":"Gemcitabine induced thrombotic microangiopathy: A systematic review","volume":"21","author":"Izzedine","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1523-1755.2005.00424.x","article-title":"NF-kappaB-dependent increase in intrarenal angiotensin II induced by proteinuria","volume":"68","author":"Takase","year":"2005","journal-title":"Kidney Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Cardiovascular toxicities panel, convened by the angiogenesis task force of the national cancer institute investigational drug steering committee: Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1188\/13.CJON.425-433","article-title":"Managing toxicities associated with antiangiogenic biologic agents in combination with chemotherapy for metastatic colorectal cancer","volume":"17","author":"Grenon","year":"2013","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/s41467-019-09936-x","article-title":"Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity","volume":"10","author":"Calizo","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1158\/1078-0432.CCR-09-0224","article-title":"Phase I dose escalation and farmacokinetic study of dasatinib in patients with advanced solid tumors","volume":"15","author":"Demetri","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3109\/10428194.2015.1075020","article-title":"Dasatinib-induced nephrotic syndrome","volume":"57","author":"Hirano","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00467-013-2696-0","article-title":"Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: Case series and review of the literature","volume":"29","author":"Ruebner","year":"2014","journal-title":"Pediatr. Nephrol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3349\/ymj.2016.57.2.532","article-title":"A case of dasatinib-induced nephrotic syndrome in a child with Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"57","author":"Lim","year":"2016","journal-title":"Yonsei Med. J."},{"key":"ref_33","unstructured":"Arceci, R.J., and Newburger, P.E. Dasatinib induced chylothorax and nephrotic syndrome in a pediatric patient. Pediatric Blood and Cancer, Proceedings of the American Society of Hematology\/Oncology (ASPHO), Phoenix, AZ, USA, 6\u20139 May 2015, Wiley Blackwell."},{"key":"ref_34","first-page":"87","article-title":"Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: A case report BMC","volume":"20","author":"Ochiai","year":"2019","journal-title":"Nephrology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1053\/j.ajkd.2013.01.022","article-title":"Dasatinib-induced nephrotic-range proteinuria","volume":"61","author":"Wallace","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"ref_36","first-page":"1106","article-title":"Nephrotic proteinuria developed under dasatinib treatment in a patient with chronic myeloid leukemia: A case report and review of the literature","volume":"3","author":"Carmosino","year":"2016","journal-title":"Ann. Hematol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Koinuma, K., Sakairi, T., Watanabe, Y., IIzuka, A., Watanabe, M., Hamatani, H., Nakasatomi, M., Ishizaki, T., Ikeuchi., H., and Kaneko, Y. (2020). A Case of long-term dasatinib-induced proteinuria and glomerular injury. CEN Case Rep.","DOI":"10.1007\/s13730-020-00484-8"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ekir.2016.09.055","article-title":"Adverse renal effects of novel molecular oncologic targeted therapies: A narrative review","volume":"2","author":"Jhaveri","year":"2017","journal-title":"Kidney Int. Rep."},{"key":"ref_39","first-page":"428","article-title":"Nephrotic syndrome under treatment with dasatinib: Be aware of a possible adverse drug reaction","volume":"75","author":"Zwaan","year":"2017","journal-title":"Neth. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/1078-0432.CCR-09-1486","article-title":"Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment","volume":"16","author":"Liang","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/01.mnh.0000437329.41546.a9","article-title":"Vascular endothelial growth factor and the kidney: Something of the marvellous","volume":"23","author":"Advani","year":"2014","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/31735","article-title":"Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization","volume":"393","author":"Yang","year":"1998","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Falkenberg, C.V., Azeloglu, E.U., Stothers, M., Deerinck, T.J., Chen, Y., He, J.C., Ellisman, M.H., Hone, J.C., Iyengar, R., and Loew, L.M. (2017). Fragility of foot process morphology in kidney podocytes arises from chaotic spatial propagation of cytoskeletal instability. PLoS Comput. Biol., 13.","DOI":"10.1371\/journal.pcbi.1005433"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1681\/ASN.2017050475","article-title":"Similar biophysical abnormalities in glomeruli and podocytes from two distinct models","volume":"29","author":"Embry","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: What do we know and what should we do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.2217\/fon-2017-0585","article-title":"Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer","volume":"14","author":"Anari","year":"2018","journal-title":"Future Oncol."},{"key":"ref_47","first-page":"4105","article-title":"Present and future of cancer immunotherapy: A tumor microenvironmental perspective","volume":"16","author":"Yu","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12929-017-0329-9","article-title":"Cancer immunotherapies targeting the PD-1 signaling pathway","volume":"24","author":"Iwai","year":"2017","journal-title":"J. Biomed. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.18632\/oncotarget.2980","article-title":"PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma","volume":"6","author":"Luke","year":"2015","journal-title":"Oncotarget"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.molmed.2015.05.005","article-title":"Checkpoint blockade for cancer therapy: Revitalizing a suppressed immune system","volume":"21","author":"Choudhury","year":"2015","journal-title":"Trends Mol. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: A meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"83","author":"Cortazar","year":"2016","journal-title":"Kidney Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_56","unstructured":"Bavi, P., Kiehl, R., Adeyi, O., Mete, O., Avila-Casado, C., Sharifzad, H., Joshua, A., Butany, J., and Roehrl, M.H. (2016, January 12\u201318). Immune-related adverse events (irAEs) following CTLA-4 and PD-1\/PD-L1 blockade in advanced melanoma: A comprehensive rapid autopsy study. Proceedings of the Annual Meeting of the United States and Canadian Academy of Pathology, Seattle, WA, USA."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab is previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/bjc.2016.358","article-title":"Acute interstitial nephritis related to immune checkpoint inhibitors","volume":"115","author":"Belliere","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/ckj\/sfw024","article-title":"Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma","volume":"9","author":"Murakami","year":"2016","journal-title":"Clin. Kidney J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40425-016-0205-2","article-title":"Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor","volume":"5","author":"Escandon","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Koda, R., Watanabe, H., Tsuchida, M., Iino, N., Suzuki, K., Hasegawa, G., Imai, N., and Narita, I. (2018). Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: A case report. BMC Nephrol., 19.","DOI":"10.1186\/s12882-018-0848-y"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"225","DOI":"10.14740\/jocmr3750","article-title":"Adverse effects of immune checkpoint inhibitors (programmed death-1 inhibitors and cytotoxic T-limphocyte- associated protein-4 inhibitors): Result of retrospective study","volume":"11","author":"Bajwa","year":"2019","journal-title":"J. Clin. Med. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: Single center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J. Immuno. Ther. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000505235","article-title":"Rapidly progressive acute kidney injury associated with nivolumab treatment","volume":"13","author":"Okawa","year":"2020","journal-title":"Case Rep. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor\u2013associated AKI: A multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_67","unstructured":"Lin, J., Schiff, M., Salvatore, S., Shoustari, A., and Glezerman, I. (2016, January 15\u201320). Membranous nephropathy related to the checkpoint inhibitor nivolumab. Proceedings of the American Society of Nephrology Kidney Week, Chicago, IL, USA."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/CJI.0000000000000189","article-title":"Nivolumab-associated nephrotic syndrome in a patient with renal cell carcinoma: A case report","volume":"40","author":"Daanen","year":"2017","journal-title":"J. Immunother."},{"key":"ref_69","unstructured":"Ray, A., Ghosh, S., Ghosh, M., and Yarlagadda, S. (2016, January 15\u201320). Nivolumab induced renal failure with collapsing focal segmental glomerulosclerosis (FSGS). Proceedings of the American Society of Nephrology Kidney Week, Chicago, IL, USA."},{"key":"ref_70","first-page":"2638283","article-title":"Membranoproliferative glomerulonephritis associated with nivolumab therapy","volume":"2020","author":"Giehl","year":"2020","journal-title":"Case Rep. Nephrol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Jung, K., Zeng, X., and Bilusic, M. (2016). Nivolumab-associated acute glomerulonephritis; a case report and literature review. BMC Nephrol., 17.","DOI":"10.1186\/s12882-016-0408-2"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2169\/internalmedicine.9814-17","article-title":"IgA nephropathy after nivolumab therapy for postoperative recurrence of squamous cell carcinoma","volume":"57","author":"Kishi","year":"2018","journal-title":"Intern. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol. Rev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/ndt\/gfh423","article-title":"Suppressed T-cell activation by IFNgamma-induced expression of PD-L1 on renal tubular epithelial cells","volume":"19","author":"Schoop","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nm.2621","article-title":"Dysregulation of immune homeostasis in autoimmune diseases","volume":"18","author":"Kuchroo","year":"2012","journal-title":"Nat. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"166","DOI":"10.34067\/KID.0001072019","article-title":"Kidney biopsy should be performed to document the cause of immune checkpoint inhibitor\u2013associated acute kidney injury: Commentary","volume":"1","author":"Perazella","year":"2020","journal-title":"Kidney360"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"162","DOI":"10.34067\/KID.0000132020","article-title":"Kidney biopsy should be performed to document the cause of immune checkpoint inhibitor\u2013associated acute kidney injury: CON","volume":"1","author":"Gutgarts","year":"2020","journal-title":"Kidney360"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"158","DOI":"10.34067\/KID.0001192019","article-title":"Kidney biopsy should be performed to document the cause of immune checkpoint inhibitor\u2013associated acute kidney injury: PRO","volume":"1","author":"Eijgelsheim","year":"2020","journal-title":"Kidney360"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e127456","DOI":"10.1172\/jci.insight.127456","article-title":"Urine TNF-a and IL-9 for clinical diagnosis of acute interstitial nephritis","volume":"4","author":"Moledina","year":"2019","journal-title":"JCI Insight"},{"key":"ref_80","first-page":"1078155220924084","article-title":"Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab","volume":"19","author":"Yekeduz","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/ndt\/gfy188","article-title":"Opening an onconephrology clinic: Recommendations and basic requirements","volume":"33","author":"Cosmai","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ekir.2017.02.008","article-title":"Anticancer drug-induced acute kidney injury","volume":"2","author":"Izzedine","year":"2017","journal-title":"Kidney Int. Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.kint.2019.02.042","article-title":"Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: Emerging evidence","volume":"96","author":"Hanna","year":"2019","journal-title":"Kidney Int."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1161\/HYPERTENSIONAHA.112.196774","article-title":"Management of antiangiogenic therapy-induced hypertension","volume":"60","author":"Robinson","year":"2012","journal-title":"Hypertension"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejca.2020.03.026","article-title":"How to determine kidney function in cancer patients?","volume":"132","author":"Sprangers","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.2017.72.7578","article-title":"New model for estimating glomerular filtration rate in patients with cancer","volume":"35","author":"Janowitz","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_87","unstructured":"(2020, June 02). Tool to Estimate Glomerular Filtration. Available online: http:\/\/tavarelab.cruk.cam.ac.UK\/JanowitzWulliamsGFR."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Okamoto, S., Ureshino, H., Kawaguchi, A., Miyazono, M., Ikeda, Y., and Kimura, S. (2020). Assessment of estimated glomerular filtration rate in patients with chronic myeloid leukemia following discontinuation of tyrosine kinase inhibitors. Int. J. Hematol., 18.","DOI":"10.1007\/s12185-020-02880-3"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Sirolli, V., Pieroni, L., Di Liberato, L., Urbani, A., and Bonomini, M. (2019). Urinary peptidomic biomarkers in kidney diseases. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21010096"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/14\/4878\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:49:48Z","timestamp":1760176188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/14\/4878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":89,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["ijms21144878"],"URL":"https:\/\/doi.org\/10.3390\/ijms21144878","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,10]]}}}